Living with transthyretin amyloid cardiomyopathy can be frightening because the disease often progresses in ways that are hard to predict. Doctors use specific markers, like NT-proBNP and sTTR, to try and understand how severe the condition is and how quickly it might progress. These markers help them see the current state of the heart muscle.
A large study of 632 patients looked at how these markers relate to the drug acoramidis. The researchers found that while high levels of one marker and low levels of another were linked to more severe disease, the drug worked consistently for everyone. This means acoramidis reduced the risk of major heart events regardless of what those initial test numbers were.
This is important because it suggests the medication provides reliable protection for patients across different stages of the disease. While the study was a look back at data already collected, it offers a clearer picture of how the drug performs for people with different baseline health profiles.
